AR056254A1 - SISTEMAS DE ADMINISTRACION INTRAOCULAR DE UNA DROGA DE LIBERACION SOSTENIDA QUE CONTIENE RETINOIDES, UN POLíMERO BIODEGRADABLE Y LOS METODOS RELACIONADOS - Google Patents

SISTEMAS DE ADMINISTRACION INTRAOCULAR DE UNA DROGA DE LIBERACION SOSTENIDA QUE CONTIENE RETINOIDES, UN POLíMERO BIODEGRADABLE Y LOS METODOS RELACIONADOS

Info

Publication number
AR056254A1
AR056254A1 ARP050101751A ARP050101751A AR056254A1 AR 056254 A1 AR056254 A1 AR 056254A1 AR P050101751 A ARP050101751 A AR P050101751A AR P050101751 A ARP050101751 A AR P050101751A AR 056254 A1 AR056254 A1 AR 056254A1
Authority
AR
Argentina
Prior art keywords
biodegradable polymer
sustained release
related methods
drug containing
release drug
Prior art date
Application number
ARP050101751A
Other languages
English (en)
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AR056254A1 publication Critical patent/AR056254A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Abstract

Los implantes intraoculares bio-compatibles incluyen un componente retinoide y un polímero bio-degradable que es efectivo para facilitar la liberacion del componente retinoide en un ojo durante un período prolongado de tiempo. Los agentes terapéuticos de los implantes pueden estar asociados con una matriz de polímero bio-degradable, tal como una matriz que está substancialmente libre de un polivinil alcohol. Los implantes pueden estar colocados en un ojo para tratar o reducir la ocurrencia de uno o más condiciones oculares, tal como el dano retinal, incluyendo el glaucoma y la vitreoretinopatía proliferativa.
ARP050101751A 2004-04-30 2005-05-02 SISTEMAS DE ADMINISTRACION INTRAOCULAR DE UNA DROGA DE LIBERACION SOSTENIDA QUE CONTIENE RETINOIDES, UN POLíMERO BIODEGRADABLE Y LOS METODOS RELACIONADOS AR056254A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56733904P 2004-04-30 2004-04-30
US62992804P 2004-11-22 2004-11-22
US11/119,024 US20050271705A1 (en) 2004-04-30 2005-04-29 Retinoid-containing sustained release intraocular drug delivery system and related methods

Publications (1)

Publication Number Publication Date
AR056254A1 true AR056254A1 (es) 2007-10-03

Family

ID=34972221

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050101751A AR056254A1 (es) 2004-04-30 2005-05-02 SISTEMAS DE ADMINISTRACION INTRAOCULAR DE UNA DROGA DE LIBERACION SOSTENIDA QUE CONTIENE RETINOIDES, UN POLíMERO BIODEGRADABLE Y LOS METODOS RELACIONADOS

Country Status (9)

Country Link
US (3) US20050271705A1 (es)
EP (1) EP1765284A1 (es)
JP (1) JP2007535563A (es)
AR (1) AR056254A1 (es)
AU (1) AU2005240078A1 (es)
BR (1) BRPI0509459A (es)
CA (1) CA2565285A1 (es)
TW (1) TW200538163A (es)
WO (1) WO2005107707A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
EP1727529B1 (en) 2004-03-17 2016-03-02 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US20070212395A1 (en) * 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
AU2005240078A1 (en) * 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US7998717B2 (en) 2005-12-02 2011-08-16 Pacific Biosciences Of California, Inc. Mitigation of photodamage in analytical reactions
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
EP2178502A2 (en) * 2007-06-21 2010-04-28 Yale University Sustained delivery of drugs from biodegradable polymeric microparticles
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
JP5591226B2 (ja) 2008-05-12 2014-09-17 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション 眼内薬物送達装置および関連する方法
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
EP2296621A1 (en) * 2008-05-20 2011-03-23 Yale University Biodegradable sustained-release polymeric microparticulates comprising a hydrophobic drug and determined for ophthalmic use
US20110206773A1 (en) * 2008-05-20 2011-08-25 Yale University Sustained delivery of drugs from biodegradable polymeric microparticles
CA2750242C (en) * 2009-02-12 2018-05-22 Incept, Llc Drug delivery through hydrogel plugs
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US8529492B2 (en) 2009-12-23 2013-09-10 Trascend Medical, Inc. Drug delivery devices and methods
US8834847B2 (en) 2010-08-12 2014-09-16 Pacific Biosciences Of California, Inc. Photodamage mitigation compounds and systems
NZ607547A (en) * 2010-09-01 2015-06-26 Univ Jefferson Composition and method for muscle repair and regeneration
US8349005B2 (en) 2011-01-03 2013-01-08 Masatoshi Murata Method for burying implant to choroid
KR20140041669A (ko) * 2011-06-03 2014-04-04 알러간, 인코포레이티드 레티노이드 화합물의 피지샘으로의 표적화된 전달
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
WO2013082149A1 (en) * 2011-11-28 2013-06-06 Case Western Reserve University Polysaccharide therapeutic conjugates
JP6254529B2 (ja) * 2012-11-08 2017-12-27 国立大学法人山口大学 角結膜障害の治療剤
WO2014085494A1 (en) * 2012-11-28 2014-06-05 Aphios Corporation Combination therapeutics and methods for the treatment of neurodegenerative and other diseases
WO2014151769A1 (en) 2013-03-15 2014-09-25 Allergan, Inc. Compositions including encapsulated isotretinoin and methods for use thereof
KR102303316B1 (ko) 2013-05-22 2021-09-23 고쿠리츠다이가쿠호우진 야마구치 다이가쿠 망막 맥락막 장해의 억제제
WO2015116709A1 (en) 2014-01-28 2015-08-06 Allergan, Inc. Topical retinoid formulations and methods of use
CA2950187A1 (en) 2014-05-29 2015-12-03 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10471118B2 (en) 2014-05-30 2019-11-12 Case Western Reserve University Retinylamine derivitives for treatment of ocular disorders
WO2015187840A2 (en) * 2014-06-03 2015-12-10 Duke University Methods and formulations for treatment of ocular disorders
US11129845B2 (en) 2014-06-18 2021-09-28 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
US10925980B2 (en) 2014-08-04 2021-02-23 Case Western Reserve University Molecular probes and methods of use
US11407786B2 (en) 2015-06-18 2022-08-09 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
CA3022830A1 (en) 2016-04-20 2017-10-26 Harold Alexander Heitzmann Bioresorbable ocular drug delivery device
IL263440B (en) 2016-06-08 2022-09-01 Clementia Pharmaceuticals Inc Methods for the treatment of heterotopic aggravation
US10980778B2 (en) 2016-11-16 2021-04-20 Clementia Pharmaceuticals Inc. Methods for treating multiple osteochondroma (MO)
CN111358766A (zh) * 2020-04-13 2020-07-03 青岛大学 一种包载他扎罗汀的plga纳米粒及其制备方法、用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824685A (en) * 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US6306426B1 (en) * 1997-08-11 2001-10-23 Allergan Sales, Inc. Implant device with a retinoid for improved biocompatibility
ES2232005T3 (es) * 1997-08-11 2005-05-16 Allergan, Inc. Dispositivo de implante biodegradable esteril que contiene retinoide con biocompatibilidad mejorada y metodo de preparacion.
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
JP2002003406A (ja) * 2000-06-21 2002-01-09 Sankyo Co Ltd 脳血管攣縮予防製剤
EP1343478B1 (en) * 2000-12-21 2007-10-10 Alrise Biosystems GmbH Induced phase transition method for the production of microparticles containing hydrophilic active agents
EP1536819A4 (en) * 2002-03-29 2007-10-17 Maxim Pharm Inc USING THE PRODUCTION OF REACTIVE OXYGEN METABOLITES (ROM) AND RELEASE INHIBITORS TO TREAT AND PREVENT INTRAOCULAR DAMAGE
US20050009910A1 (en) * 2003-07-10 2005-01-13 Allergan, Inc. Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
AU2005240078A1 (en) * 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing

Also Published As

Publication number Publication date
CA2565285A1 (en) 2005-11-17
BRPI0509459A (pt) 2007-09-04
US20110076318A1 (en) 2011-03-31
JP2007535563A (ja) 2007-12-06
AU2005240078A1 (en) 2005-11-17
EP1765284A1 (en) 2007-03-28
TW200538163A (en) 2005-12-01
US20090163550A1 (en) 2009-06-25
WO2005107707A1 (en) 2005-11-17
US20050271705A1 (en) 2005-12-08

Similar Documents

Publication Publication Date Title
AR056254A1 (es) SISTEMAS DE ADMINISTRACION INTRAOCULAR DE UNA DROGA DE LIBERACION SOSTENIDA QUE CONTIENE RETINOIDES, UN POLíMERO BIODEGRADABLE Y LOS METODOS RELACIONADOS
TW200603775A (en) Anti-excitotoxic sustained release intraocular implants and related methods
CO6351718A2 (es) Suministro de liberacion sostenida de agentes activos para tratar glaucoma e hipertension ocular
CO6400201A2 (es) Suministro liberado sostenido de uno o más agentes
AR062046A1 (es) Soluciones oftalmicas
TW200605918A (en) Biodegradable intravitreal tyrosine kinase implants
BRPI0510471A (pt) derivado de estradiol ou um derivado de estratopona contendo implante intra-ocular de liberação constante bem como métodos relacionados de fabricação
CO2017007003A2 (es) Formulaciones de sunitinib y métodos para uso de las mismas en el tratamiento de trastornos oculares
AR064078A1 (es) Sistema de administracion de farmacos intraocular inyectable biocompatible, su uso para preparar un medicamento y proceso para su preparacion
AR049979A1 (es) Composicion oftalmica util para la colocacion intraocular en un ojo de un ser humano o animal y uso de un componente corticosteroide, un componente polimerico biocompatible y un componente solvente oftalmicamente compatible en una cantidad efectiva para solubilizar el componente polimerico para prep
AR063619A1 (es) Dispositivos y metodos para la administraicion de un farmaco oftalmico
CL2016001041A1 (es) Implante intraocular biodegradable que contiene una matriz de polimero biodegradable, polietilenglicol 3350 y una prostamida; uso del mismo en la reducción de la presion ocular en el ojo de un mamifero; aparato para administrar el implante intraocular biodegradable; y método para confeccionar un implante intraocular biodegradable.
WO2005107706A3 (en) Biodegradable intravitreal tyrosine kinase inhibitors implants
NZ595349A (en) Nasolacrimal drainage system implants for drug therapy with drug core within sheath and expandable body
Robert et al. A review of corneal melting after Boston Keratoprosthesis
BR112015019546A2 (pt) implante de distribuição de drogas prolongado
EA201300272A1 (ru) Применение фотоусиливающих агентов в ассоциации с рибофлавином, а также соответствующих офтальмологических композиций для перекрестного сшивания роговицы при лечении кератоконуса или других эктазийных расстройств роговицы
BR112012026535A2 (pt) redução de pressão intraocular com implantes de bimatoprost intracameral
AR085781A1 (es) Dispositivo y metodo para el suministro corneal de riboflavina mediante iontoforesis para el tratamiento de queratocono
WO2008060359A3 (en) Biodegradable ocular implants and methods for treating ocular conditions
JP2011525388A5 (es)
AR043356A1 (es) Dispositvo de liberacion sostenida para la administracion ocular de inhibidores de la anhidrasa carbonica y uso de inhibidores de la anhidrasa carbonica para su preparacion
MX2021013428A (es) Insertos oculares polimericos disolubles y metodo de uso de los mismos.
BR112013018739A2 (pt) sistema de distribuição de medicamento ocular
CY1123344T1 (el) Μεθοδοι αγωγης οφθαλμικων καταστασεων με ενα εμφυτευμα κατακρατημενης απελευθερωσης φαρμακων

Legal Events

Date Code Title Description
FA Abandonment or withdrawal